HighTower Advisors LLC Makes New $121,000 Investment in Roivant Sciences Ltd. (NASDAQ:ROIV)

HighTower Advisors LLC acquired a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 10,213 shares of the company’s stock, valued at approximately $121,000.

Several other hedge funds and other institutional investors have also modified their holdings of ROIV. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Roivant Sciences by 17.4% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 93,121 shares of the company’s stock valued at $1,102,000 after buying an additional 13,834 shares during the period. Amundi increased its position in shares of Roivant Sciences by 15.0% in the fourth quarter. Amundi now owns 337,515 shares of the company’s stock worth $3,719,000 after acquiring an additional 44,019 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in shares of Roivant Sciences by 27.0% in the 4th quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company’s stock valued at $84,000 after acquiring an additional 1,507 shares during the period. E Fund Management Co. Ltd. lifted its holdings in shares of Roivant Sciences by 20.3% during the 4th quarter. E Fund Management Co. Ltd. now owns 50,647 shares of the company’s stock valued at $599,000 after acquiring an additional 8,535 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in Roivant Sciences during the 4th quarter worth $995,000. 64.76% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Sciences Ltd. Roivant purchased 16,845,010 shares of the firm’s stock in a transaction that occurred on Monday, January 13th. The stock was acquired at an average cost of $20.00 per share, for a total transaction of $336,900,200.00. Following the completion of the purchase, the director now owns 96,650,341 shares of the company’s stock, valued at approximately $1,933,006,820. This trade represents a 21.11 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Eric Venker sold 100,000 shares of the business’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $11.28, for a total value of $1,128,000.00. Following the completion of the sale, the chief operating officer now directly owns 732,294 shares of the company’s stock, valued at approximately $8,260,276.32. This represents a 12.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 1,395,541 shares of company stock worth $15,028,538. 7.90% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Cantor Fitzgerald upgraded Roivant Sciences to a “strong-buy” rating in a research note on Tuesday, March 4th. HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a research report on Tuesday, February 11th.

Roivant Sciences Price Performance

NASDAQ:ROIV opened at $9.46 on Friday. The firm has a 50-day moving average of $10.62 and a two-hundred day moving average of $11.33. The stock has a market cap of $6.75 billion, a P/E ratio of -63.06 and a beta of 1.26. Roivant Sciences Ltd. has a 1-year low of $9.42 and a 1-year high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings results on Monday, February 10th. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. As a group, equities analysts expect that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.